Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Astellas Collaborates with Ambrx for Discovery and Development of Novel ADCs for Oncology Fields
April 9, 2013
- Novo Nordisk’s FY2012 Sales Dip 0.8% with Insulin Market Subdued by DPP-4 Inhibitors
April 8, 2013
- Abbott Japan Sales Decline 3.2% in 2012 Due to Product Transfer to AbbVie
April 8, 2013
- Survey by JCSOA Finds Big Increase in Use of CMRs to Detail Long-Listed and Non-Priority Products
April 8, 2013
- Teijin Acquires 10% Stake in Kyorin for Strategic Alliance
April 8, 2013
- Bell Medical Solutions Concludes Business Alliance Agreement for CRO Business with inVentiv Health Clinical
April 8, 2013
- Allegra Generic Versions Expected to Be Further Promoted: Pharmacist Survey
April 5, 2013
- Takeda to Successively File 2 New Diabetes Drugs in Japan
April 5, 2013
- MPD Begins Marketing BindRen in Germany and Austria
April 5, 2013
- Daiichi Sankyo Ends ATK Inhibitor Agreement with ArQule
April 5, 2013
- AnGes to Acquire Exclusive Rights for CIN Therapeutic Vaccine for Cervical Precancerous Lesions in Major Countries
April 5, 2013
- MTPC Agrees to Transfer Tanabe Europe Shares to API in Tokyo
April 4, 2013
- Protected Drugs Represent More than 50% of Bayer Yakuhin Sales in 2012, Over 60% Eyed by 2014: Pres. Brunn
April 4, 2013
- Mochida Aims at Sales of 104 Billion Yen in FY2015
April 4, 2013
- Presidents of Pharmaceutical Companies Stress Globalization, Compliance in Welcoming Ceremonies for New Employees
April 4, 2013
- Nihon Chouzai to Make Choseido Subsidiary, to Sell Its Products Through Nihon Generic
April 4, 2013
- Plavix Rises to 3rd Place in Domestic Ethical Drug Market in 2012, Could Take No. 1 Spot This Year
April 4, 2013
- MSD Reports Downturn in Profits for 2012 Despite 2.7% Growth in Sales
April 3, 2013
- AZ K.K. Reports 5.1% Decline in 2012 Sales; Sales of Omepral and Casodex Down
April 3, 2013
- Bayer Yakuhin Reports Nearly 20% Drop in Operating Profit Despite Growth in Sales of Zetia
April 3, 2013
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…